TRPC5 and focal segmental glomerulosclerosis: TRPC6 inhibition is currently studied in patients with FSGS (NCT05213624), whereas GFB-887, an inhibitor of TRPC5, was investigated as a potential therapeutic agent in FSGS and MCD (NCT04387448) in a phase 2 trial, which had to be terminated prematurely due to business reasons.